KCB-328

KCB-328 is a small molecule class III antiarrhythmic agent originally developed by C&C Research Laboratories (now JW C&C Research Lab). It acts as a selective blocker of the rapid component of the delayed rectifier potassium current (IKr), which is encoded by the human ether-a-go-go-related gene (hERG) channel. Unlike typical class III antiarrhythmics such as dofetilide, KCB-328 exhibits minimal reverse frequency dependence (RFD), meaning its action potential duration (APD) prolongation effect is maintained at higher heart rates with a lower risk of inducing torsades de pointes. Although it demonstrated promising efficacy and a favorable safety profile in preclinical models of atrial fibrillation and atrial flutter, its development has been discontinued.

Other names

1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane hydrochloride